scholarly journals Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

Cancer ◽  
2017 ◽  
Vol 123 (16) ◽  
pp. 3141-3149 ◽  
Author(s):  
Jeffrey R. Schriber ◽  
Parameswaran N. Hari ◽  
Kwang Woo Ahn ◽  
Mingwei Fei ◽  
Luciano J. Costa ◽  
...  
Keyword(s):  
United States ◽  
Multiple Myeloma ◽  
Stem Cell ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Stem Cell Transplant ◽  
The United States ◽  
Utilization Rate ◽  
Cell Transplant ◽  
Autologous Hematopoietic Cell Transplantation

Rates and Predictors of Stem Cell Transplant in Elderly Medicare Beneficiaries with Multiple Myeloma in the United States

2017 ◽  
Vol 17 (1) ◽  
pp. e55
Author(s):  
Candice Yong ◽  
Jean Yared ◽  
Daisuke Goto ◽  
Eberechukwu Onukwugha ◽  
Rahul Khairnar ◽  
...  
Keyword(s):  
United States ◽  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
The United States ◽  
Cell Transplant ◽  
Medicare Beneficiaries

Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3469-3469
Author(s):  
Morie Abraham Gertz ◽  
Dennis Gastineau ◽  
Martha Lacy ◽  
Angela Dispenzieri ◽  
Suzanne R. Hayman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Growth Factors ◽  
Growth Factor ◽  
Research Funding ◽  
Stem Cell Transplant ◽  
The United States ◽  
Median Number ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant

Abstract Abstract 3469 Introduction: Stem cell transplantation is important in the management of multiple myeloma. In the United States, the standard of care is administration of growth factors to accelerate neutrophil recovery after stem cell transplant. The need for growth factors after transplant has not been investigated recently. Patients: We analyzed a cohort of 166 patients at our institution who underwent autologous transplant for multiple myeloma without receiving growth factors after transplant and compared them with 498 patients who received standard filgrastim beginning on posttransplant day 5. TABLE Results: A neutrophil count of 500/μL was achieved in a median of 12.5 days in patients receiving growth factor, compared with 13.5 days in those not receiving growth factor (P<.001) Fig 1. Platelet engraftment was identical (median, 14.5 days; P=.12) in both groups, despite a lower median number of CD34+ cells infused in patients who did not receive growth factors. Incidence of nonstaphylococcal bacteremia was identical in both groups. The median hospital stay was 3.5 days shorter in the group not receiving growth factor. Bacteremia impacted platelet but not neutrophil engraftment. Figure 2 Conclusion: It is feasible and reasonable to perform autologous stem cell transplant for multiple myeloma without administering growth factors. Estimated savings would be $4,600 for each transplanted patient. Growth factor administration is not required for a safe outcome and decreases the number and severity of some of the fluid-related complications after transplant such as acute respiratory distress syndrome, allergic reactions, alveolar hemorrhage, and rarely splenic rupture. Disclosures: Gertz: Celgene: Honoraria; Millenium: Honoraria, Membership on an entity's Board of Directors or advisory committees. Lacy:Celgene: Research Funding. Dispenzieri:Celgene: Honoraria, Research Funding; Binding Site: Honoraria. Kumar:Celgene: Consultancy, Research Funding; Millennium: Research Funding; Merck: Consultancy, Research Funding; Novartis: Research Funding; Genzyme: Consultancy, Research Funding; Cephalon: Research Funding.

Sign in / Sign up

Export Citation Format

Share Document